Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

Description

The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.

Conditions

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.

A Study to Determine the Prevalence and Clinical Characteristics Associated With PKD1 Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

Condition
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention / Treatment

-

Contacts and Locations

Alabaster

Alabama Kidney Research, Alabaster, Alabama, United States, 35007

Inverness

Nature Coast Clinical Research - Inverness, Inverness, Florida, United States, 34452

Columbus

Renal Associates, LLC, Columbus, Georgia, United States, 31904

Farmington Hills

Quest Research Institute, Farmington Hills, Michigan, United States, 48334

Las Vegas

DaVita Clinical Research, Las Vegas, Nevada, United States, 89107

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 30 milliliter per minute (mL/min)/1.73 m\^2
  • * Willing and able to comply with scheduled visits and other study procedures
  • * A pre-existing diagnosis of ADPKD as defined in the protocol
  • * History of kidney disease other than ADPKD that in the opinion of the investigator would independently impact the natural history of ADPKD
  • * History of solid organ or bone marrow transplantation or nephrectomy
  • * Ongoing renal replacement therapy or planning to start renal replacement therapy less than or equal to (≤)12 months from the Genotyping Visit in Part A

Ages Eligible for Study

12 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Vertex Pharmaceuticals Incorporated,

Study Record Dates

2026-12